Quick summary: TECENTRIQ (atezolizumab) - Risk of Myocarditis .
Public recall detail
TECENTRIQ (atezolizumab) - Risk of Myocarditis
Recall
Safety notice
Quick summary
Recommended action
Recommended action: compare your product with the official notice and follow the instructions published by the official source.
Recall details
Quick summary: TECENTRIQ (atezolizumab) - Risk of Myocarditis .
Official details
Affected product details
Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.
Brand
Affected products
Issue
Severe cases of myocarditis have been reported in patients receiving TECENTRIQ treatment.
What you should do
Additional official information
Background{}
Companies
Audiences
Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.
FAQ
Frequently asked questions
Answers based on the official recall notice.
Product images
Official product images from Health Canada.
Starting...
Explore more
Related recalls
Similar recalls and safety notices.